Specific peripheral B cell tolerance defects in patients with multiple sclerosis

Journal of Clinical Investigation

Volumn 123, Issue 6, 2013, Pages 2737-2741

  Kinnunen, Tuure ^a,b   Chamberlain, Nicolas ^a   Morbach, Henner ^a   Cantaert, Tineke ^a   Lynch, Megan ^a   Preston Hurlburt, Paula ^a   Herold, Kevan C ^a   Hafler, David A ^a   O'Connor, Kevin C ^a   Meffre, Eric ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; B LYMPHOCYTE RECEPTOR; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; BONE MARROW CELL; CELL CLONING; CELL MATURATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; IPEX SYNDROME; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; WHITE MATTER;

ANTIGENS, CD; AUTOANTIGENS; B-LYMPHOCYTES; CASE-CONTROL STUDIES; FLOW CYTOMETRY; HUMANS; MULTIPLE SCLEROSIS; PERIPHERAL TOLERANCE; T-LYMPHOCYTES, REGULATORY;

EID: 84878549686     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI68775     Document Type: Article

References (23)

1. Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012;122(4):1180-1188.
2. Büdingen von H-C, Bar-Or A, Zamvil SS. B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol. 2011;23(6):713-720.
3. Hauser SL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676-688.
4. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B-cell precursors. Science. 2003;301(5638):1374-1377.
5. Samuels J, Ng Y-S, Coupillaud C, Paget D, Meffre E. Impaired early B-cell tolerance in patients with rheumatoid arthritis. J Exp Med. 2005;201(10):1659-1667.
6. Menard L, et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest. 2011;121(9):3635-3644.
7. Edwards JCW, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-2581.
8. Pescovitz MD, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009;361(22):2143-2152.
9. Hervé M, et al. CD40 ligand and MHC class II expression are essential for human peripheral B-cell tolerance. J Exp Med. 2007;204(7):1583- 1593.
10. Isnardi I, et al. IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity. 2008;29(5):746-757.
11. Sauer AV, Morbach H, Brigida I, Ng Y-S, Aiuti A, Meffre E. Defective B-cell tolerance in adenosine deaminase deficiency is corrected by gene therapy. J Clin Invest. 2012;122(6):2141-2152.
12. Kinnunen T, et al. Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood. 2013;121(9):1595-1603.
13. van Zelm MC, Szczepanski T, van der Burg M, van Dongen JJM. Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B-cell expansion. J Exp Med. 2007;204(3):645-655.
14. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009;9(7):491-502.
15. Haas J, et al. Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J Immunol. 2007;179(2):1322-1330.
16. Venken K, Hellings N, Broekmans T, Hensen K, Rummens J-L, Stinissen P. Natural naive CD4+CD25+ CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J Immunol. 2008;180(9):6411-6420.
17. Cotsapas C, et al. Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet. 2011;7(8):e1002254.
18. Rieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum C, Concannon P, Buckner JH. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol. 2007;179(7):4704-4710.
19. Arechiga AF, et al. Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol. 2009;182(6):3343-3347.
20. Cho JH, Gregersen PK. Genomics and the multifactorial nature of human autoimmune disease. N Engl J Med. 2011;365(17):1612-1623.
21. Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214-219.
22. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004;199(7):971-979.
23. Dominguez-Villar M, Baecher-Allan CM, Hafler DA. Identification of T helper type 1-like, Foxp3(+) regulatory T cells in human autoimmune disease. Nat Med. 2011;17(6):673-675.